Abstract: The present disclosure provides CRISPR-Cas effector polypeptides that exhibit enhanced gene editing and/or trans cleavage activity, compared to a wild-type CasPhi polypeptide. The present disclosure provides systems and kits comprising such CRISPR-Cas effector polypeptides. The present disclosure provides methods, including gene editing and diagnostic methods, using a CRISPR-Cas effector polypeptide of the present disclosure.

Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid. The present disclosure provides methods of detecting a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA.